TOP - Daily
SAN DIEGO—Current or recent tamoxifen therapy was associated with an increased risk of developing type 2 diabetes in women older than 65 years who survived invasive breast cancer. No association was found between aromatase inhibitors (AIs) and development of type 2 diabetes, but the numbers of women on AIs was small. These findings of a population-based, case-control study in Toronto, Ontario, Canada, were presented at the 71st Scientific Sessions of the American Diabetes Association.
Read More ›I would like to welcome everyone to the inaugural edition of “Koeller’s Corner.” The intent is for this to be a regular column for The Oncology Pharmacist. For this introductory edition, I would like to introduce myself to the readers and describe the intent of my column as we move forward.
First, my name is Jim Koeller, and I am currently a full professor at the University of Texas at Austin College of Pharmacy and an adjoint professor of medicine and oncology at the University of Texas Health Science Center in San Antonio.
Read More ›Cell surfaces and many biologically active molecules are covered with sugar structures that are involved in communication, immunity, and inflammation. Likewise, sugars attached to drugs can enhance, change or neutralize the drug’s effects, says Jon Thorson, a professor of pharmaceutical sciences at the University of Wisconsin-Madison School of Pharmacy.
As an expert in the attachment and function of these sugars, Thorson says there is major potential for improving drugs simply by understanding and controlling the sugars.
Read More ›On September 19-20, 2011, world leaders will convene at the United Nations in New York for the second ever high-level meeting on a specific health issue to chart a global response to noncommunicable diseases (NCDs). These challenging diseases – cancer, cardiovascular disease, chronic respiratory disease, and diabetes – with common risk factors that include smoking, alcohol abuse, physical inactivity, and unhealthy diet, now cause 63% of all deaths globally, 90% of which occur in developing countries.
Read More ›Urothelial (transitional) bladder carcinoma, the most common type of bladder cancer, has mutations in genes that function in chromatin remodeling, affecting the way DNA is packaged, duplicated, and processed during cell division. Gui et al from China examined this issue in a study just published online in Nature Genetics. Common chromatin remodeling genes include UTX, MLL-MLL3, CREBBP-EP300, NCOR1, ARID1A, and CHD6. Read More ›
A new RNAi Center at the La Jolla Institute for Allergy & Immunology will advance scientific efforts in identifying the specific genes involved in causing cancer and other diseases. Utilizing a Nobel Prize–winning technology known as RNA interference (RNAi), the Institute’s new RNAi Center will be a catalyst for accelerating discovery of new therapies against a variety of diseases. The center is one of a small, select group of dedicated RNAi facilities worldwide.
Read More ›